Skip to main content

Table 1 Clinical characteristics: the high VDJ% group includes more patients with ASCT than with conventional chemotherapy

From: In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival

 

Untreated/ Chemo

RR/Chemo

Untreated/ASCT

RR/ASCT

High VDJ%

16

24

28

1

Low VDJ%

24

25

21

0

Total

40

49

49

1

  1. VDJ% in patients whose BM aspirates were taken at diagnosis or relapse and who ultimately received either conventional chemotherapy or ASCT.